摘要
目的:系统评价阿戈美拉汀与度洛西汀治疗首发抑郁障碍患者的疗效和安全性的差异。方法:运用中国知网(CNKI)、维普(VIP)、万方、PubMed、Web of Science等数据库进行检索,纳入两种药物治疗首发抑郁障碍的头对头临床随机对照研究,提取疗效和安全性的数据,采用RevMan 5.4进行meta分析。结果:共纳入6篇文章。meta分析结果显示,治疗后阿戈美拉汀组与度洛西汀组HAMD-17评分差异(P<0.05)、总有效率差异(P=0.002)有统计学意义,治愈率差异(P=0.10)、总不良反应发生率差异(P=0.11)无统计学意义。结论:与度洛西汀相比,阿戈美拉汀治疗首发抑郁障碍的安全性相当,疗效具有优势。
Objective:To systematically evaluate the difference in efficacy and safety of duloxetine and agomelatine in the treatment of patients with first-episode depression.Methods:The head-to-head clinical randomized controlled studies of two drugs in patients with first-episode depression were included by searching in the National Knowledge Infrastructure Database(CNKI),VIP,Wanfang,PubMed,Web of Science and other databases,the data on the efficacy and safety were extracted,and meta-analysis was performed using RevMan 5.4.Results:A total of 6 papers were included.Meta-analysis showed that there were significant differences in the HAMD-17 scores(P<0.05)and effective rate between the agomelatine group and the duloxetine group after treatment(P=0.002),however,the difference in cure rate(P=0.10)and the incidence of total adverse reactions(P=0.11)were not statistically significant.Conclusion:Agomelatine for the treatment of first-episode depression has comparable safety and superior efficacy compared with duloxetine.
作者
汪倩
刘永军
WANG Qian;LIU Yongjun(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China)
出处
《上海医药》
CAS
2024年第9期23-28,共6页
Shanghai Medical & Pharmaceutical Journal
